KCNN4 and head and neck cancer: Likewise, pembrolizumab, which is a humanized monoclonal antibody with high specificity towards PD-1, has been used in the treatment of several malignancies, including head and neck cancer [182], and increases KCNN4 channel activity and CD8 T-cell chemotaxis (Table 2) [132].